ALK	anaplastic lymphoma kinase
CCI	Charlson comorbidity index
ccRCC	clear cell renal cell cancer
CDCs	collecting duct carcinomas
ChRCC	chromophobe renal cell cancer
CR	complete response
ctDNA	circulating tumor DNA
CXCR4	CXC-chemokine receptor-4
dBP	diastolic blood pressure
DOR	duration of response
EMA	European medical agency
ESMO	European society for medical oncology
FDA	food and drug administration
FFS	failure free survival
HIF	hypoxia-inducible factor
HLRCC	hereditary leiomyomata and renal cell cancer
ICI	immune checkpoint inhibitors
IFN	interferon
IL-2	interleukin-2
IMDC	International Metastatic RCC Database Consortium
ITT	intention to treat
NCCN	national comprehensive cancer network
ORR	objective response rate
OS	overall survival
PD-1	programmed cell death-1
PD-L1	programmed cell death-ligand 1
PFS	progression free survival
PRCC	papillary renal cell cancer
RCC	renal cell cancer
RFS	relapse free survival;
RMC	renal medullary carcinoma
ROS1, ROS	proto-oncogene 1 receptor tyrosine kinase
SEER	surveillance epidemiology and end results
TKIs	tyrosine kinase inhibitors
TMB	tumor mutational burden
TRCC	translocation renal cell carcinoma
TSC	tuberous sclerosis complex
TTF	time to treatment failure
TTR	time to treatment response
VEGFr	vascular endothelial growth factor receptor
VHL	Von Hippel-Lindau